[go: up one dir, main page]

NO983002L - Vitronectin-reseptor-antagonister - Google Patents

Vitronectin-reseptor-antagonister

Info

Publication number
NO983002L
NO983002L NO983002A NO983002A NO983002L NO 983002 L NO983002 L NO 983002L NO 983002 A NO983002 A NO 983002A NO 983002 A NO983002 A NO 983002A NO 983002 L NO983002 L NO 983002L
Authority
NO
Norway
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
osteoporosis
compounds
Prior art date
Application number
NO983002A
Other languages
English (en)
Norwegian (no)
Other versions
NO983002D0 (no
Inventor
Fadia E Ali
William E Bondinell
Richard M Keenan
Thomas W Ku
William H Miller
James Samanen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO983002D0 publication Critical patent/NO983002D0/no
Publication of NO983002L publication Critical patent/NO983002L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
NO983002A 1995-12-29 1998-06-26 Vitronectin-reseptor-antagonister NO983002L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US953295P 1995-12-29 1995-12-29
PCT/US1996/020744 WO1997024122A1 (en) 1995-12-29 1996-12-20 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
NO983002D0 NO983002D0 (no) 1998-06-26
NO983002L true NO983002L (no) 1998-08-26

Family

ID=21738237

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983002A NO983002L (no) 1995-12-29 1998-06-26 Vitronectin-reseptor-antagonister

Country Status (16)

Country Link
EP (1) EP0895475A4 (cs)
JP (1) JP2000502708A (cs)
KR (1) KR19990076876A (cs)
CN (1) CN1209060A (cs)
AU (1) AU1353897A (cs)
BR (1) BR9612378A (cs)
CA (1) CA2241724A1 (cs)
CZ (1) CZ203798A3 (cs)
HU (1) HUP9901116A2 (cs)
IL (1) IL125034A0 (cs)
MX (1) MX9805253A (cs)
NO (1) NO983002L (cs)
PL (1) PL327919A1 (cs)
TR (1) TR199801255T2 (cs)
WO (1) WO1997024122A1 (cs)
ZA (1) ZA9610855B (cs)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0777657A1 (en) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
WO1997026250A1 (en) * 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
DE69716900T2 (de) * 1996-04-10 2003-07-03 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTEN
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
CA2297910A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
PE20000323A1 (es) * 1998-03-10 2000-05-24 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
AU760771B2 (en) * 1998-04-01 2003-05-22 Janssen Pharmaceutica N.V. PDE IV inhibiting pyridine derivatives
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
SE9803518D0 (sv) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
MXPA02000722A (es) 1999-07-21 2002-07-22 Wyeth Corp Antagonistas biciclicos selectivos para la integrina alfav beta3.
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2800067B1 (fr) * 1999-10-21 2004-12-17 Rhodia Chimie Sa Intermediaires de fabrication d'un derive de type benzofurane ou benzothiophene nitre en position 5 et leurs utilisations
FR2820743B1 (fr) 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006041046A1 (ja) * 2004-10-13 2006-04-20 Sankyo Company, Limited ピリジン誘導体
BRPI0610506A2 (pt) 2005-04-20 2010-06-29 Johnson & Johnson moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EA201200560A1 (ru) 2006-01-18 2012-09-28 Мерк Патент Гмбх Специфическая терапия, использующая интегриновые лиганды для лечения рака
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
EP2441464B1 (en) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
US8648066B2 (en) 2009-05-22 2014-02-11 Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
WO2011082967A1 (de) * 2009-12-17 2011-07-14 Basf Se Verfahren zur herstellung von höheren ethanolaminen
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
MX2016015467A (es) 2014-05-30 2017-03-23 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
MA45244A (fr) 2016-06-13 2019-04-17 Cancer Research Tech Ltd Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
EP3589627A4 (en) * 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. (ALPHA-V) (BETA-6) INHIBITORS INTEGRIN
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
PL3844162T3 (pl) 2018-08-29 2025-06-09 Morphic Therapeutic, Inc. Inhibitory integryny alfa v beta 6
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627754A (en) * 1970-05-13 1971-12-14 Hoffmann La Roche Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts
JP3497164B2 (ja) * 1991-06-28 2004-02-16 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノーゲン拮抗薬
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
ZA9610853B (en) * 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
CZ203898A3 (cs) * 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití

Also Published As

Publication number Publication date
JP2000502708A (ja) 2000-03-07
AU1353897A (en) 1997-07-28
TR199801255T2 (xx) 1998-10-21
EP0895475A4 (en) 2000-08-23
KR19990076876A (ko) 1999-10-25
ZA9610855B (en) 1997-11-24
CN1209060A (zh) 1999-02-24
EP0895475A1 (en) 1999-02-10
WO1997024122A1 (en) 1997-07-10
CA2241724A1 (en) 1997-07-10
HUP9901116A2 (hu) 2000-03-28
NO983002D0 (no) 1998-06-26
CZ203798A3 (cs) 1998-12-16
MX9805253A (es) 1998-10-31
PL327919A1 (en) 1999-01-04
IL125034A0 (en) 1999-01-26
BR9612378A (pt) 1999-07-13

Similar Documents

Publication Publication Date Title
NO983002L (no) Vitronectin-reseptor-antagonister
NO983003L (no) Vitronectin-reseptor-antagonister
TR199800585T2 (xx) COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar.
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
GB9514473D0 (en) Chemical compounds
TR200000333T2 (tr) Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
MX9702070A (es) Nuevos inhibidores de resorcion osea y antagonistas de receptor de vitronectina.
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
ATE314371T1 (de) Spiro-indole als y5-rezeptor antagonisten
GB0031103D0 (en) Chemical compounds
ES2163638T3 (es) Nuevas n-(1-alquil-5-fenil-2,3,4,5-tetrahidro-1h-benzo(b)(1,5)diacepin-3-il)acetamidas.
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
SE9702773D0 (sv) Novel compounds
NO20001514L (no) Vitronectin-reseptor-antagonist
TR200002896T2 (tr) Kalsilitik Bileşimler
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
NO20001515L (no) Vitronektin reseptor-antagonist
FI974640A0 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application